ADC Therapeutics SA
ADCT4.460USD
-0.175-3.78%
收盘 10/31, 16:00（美东）报价延迟15分钟
501.75M总市值
亏损市盈率 TTM
关于 ADC Therapeutics SA 公司
ADC Therapeutics SA 是一家总部位于瑞士的临床阶段肿瘤药物发现和开发公司。该公司开发抗体药物偶联物 (ADC)，用于治疗实体癌和血液癌。该公司采用针对特定肿瘤抗原的单克隆抗体与一类基于吡咯并苯二氮卓 (PBD) 的弹头结合，以选择性地靶向和杀死癌细胞。该公司有多个基于 PBD 的 ADC 正在进行临床试验，从首次人体试验到关键的 II 期临床试验，以及许多正在开发的临床前 ADC。其主要候选药物是用于治疗淋巴瘤和白血病的 ADCT-301 和用于治疗非霍奇金淋巴瘤和 B 细胞白血病的 ADCT-402。该公司为美国、瑞士和英国的客户提供服务。
ADC Therapeutics SA简介
公司代码ADCT
公司名称ADC Therapeutics SA
上市日期May 15, 2020
CEOMr. Ameet Mallik
员工数量263
证券类型Ordinary Share
年结日May 15
公司地址Biopole
城市EPALINGES
上市交易所NYSE Consolidated
国家Switzerland
邮编1066
电话41216530200
网址https://adctherapeutics.com/
公司代码ADCT
上市日期May 15, 2020
CEOMr. Ameet Mallik
ADC Therapeutics SA公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.50K
+26.54%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
+38.35%
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
+38.06%
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
55.26K
+98.35%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Director
Director
40.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
+1.60%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
1.55M
-1.70%
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
642.33K
+50.70%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
404.81K
+0.52%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
361.04K
-11.63%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.50K
+26.54%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月2日 周四
更新时间: 10月2日 周四
持股股东
股东类型
持股股东
持股股东
占比
Redmile Group, LLC
13.93%
Prosight Capital
9.30%
HPWH TH AG
7.71%
Point72 Asset Management, L.P.
6.90%
OrbiMed Advisors, LLC
5.25%
其他
56.91%
持股股东
持股股东
占比
Redmile Group, LLC
13.93%
Prosight Capital
9.30%
HPWH TH AG
7.71%
Point72 Asset Management, L.P.
6.90%
OrbiMed Advisors, LLC
5.25%
其他
56.91%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
22.78%
Hedge Fund
19.46%
Corporation
9.69%
Investment Advisor
9.20%
Research Firm
6.61%
Individual Investor
5.81%
Private Equity
5.25%
Bank and Trust
0.86%
Insurance Company
0.02%
其他
20.31%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
184
72.23M
64.20%
+2.08M
2025Q2
209
87.64M
88.37%
-14.63M
2025Q1
217
80.51M
81.56%
-23.93M
2024Q4
219
81.03M
83.80%
-19.29M
2024Q3
223
79.78M
82.57%
-21.86M
2024Q2
215
76.61M
81.35%
-7.96M
2024Q1
177
59.13M
71.30%
-27.56M
2023Q4
169
58.32M
71.49%
-25.86M
2023Q3
180
68.48M
85.02%
-18.63M
2023Q2
182
74.11M
92.00%
-12.88M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Redmile Group, LLC
15.67M
13.93%
--
--
Jun 30, 2025
Prosight Capital
10.47M
9.3%
+924.77K
+9.69%
Jun 30, 2025
HPWH TH AG
8.67M
7.71%
-1.12M
-11.42%
May 15, 2025
Point72 Asset Management, L.P.
7.76M
6.9%
+7.76M
--
Jun 30, 2025
OrbiMed Advisors, LLC
5.91M
5.25%
-61.10K
-1.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.06M
3.6%
-442.92K
-9.85%
Jun 30, 2025
Oaktree Capital Management, L.P.
4.02M
3.57%
+4.02M
--
Apr 25, 2024
Morgan Stanley & Co. LLC
2.99M
2.66%
+33.76K
+1.14%
Jun 30, 2025
Heights Capital Management, Inc.
2.83M
2.52%
+2.83M
--
Jun 30, 2025
Nantahala Capital Management, LLC
2.27M
2.01%
+2.27M
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
iShares Micro-Cap ETF
0.05%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.05%
iShares Biotechnology ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Fidelity Enhanced Small Cap ETF
占比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
